KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Invested Capital (2017 - 2026)

Aquestive Therapeutics has reported Invested Capital over the past 9 years, most recently at $11.3 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 174.81% year-over-year to $11.3 million; the TTM value through Dec 2025 reached $11.3 million, up 174.81%, while the annual FY2025 figure was $11.3 million, 174.81% up from the prior year.
  • Invested Capital for Q4 2025 was $11.3 million at Aquestive Therapeutics, up from $2.2 million in the prior quarter.
  • Over five years, Invested Capital peaked at $11.3 million in Q4 2025 and troughed at -$93.6 million in Q3 2022.
  • A 5-year average of -$48.1 million and a median of -$61.2 million in 2023 define the central range for Invested Capital.
  • Biggest five-year swings in Invested Capital: crashed 2767.63% in 2021 and later surged 628.1% in 2025.
  • Year by year, Invested Capital stood at -$80.1 million in 2021, then grew by 16.3% to -$67.1 million in 2022, then grew by 8.3% to -$61.5 million in 2023, then skyrocketed by 75.35% to -$15.2 million in 2024, then surged by 174.81% to $11.3 million in 2025.
  • Business Quant data shows Invested Capital for AQST at $11.3 million in Q4 2025, $2.2 million in Q3 2025, and -$69.4 million in Q2 2025.